News for Replimune Group, Inc. (REPL)

Operator: Good morning and welcome to the Replimune Fiscal Year Fourth Quarter 2025 Financial Results and Corporate Update Conference Call. Currently, all participants are in listen-only mode.

Replimune (REPL) has initiated a filing for a $250 million mixed securities shelf. This strategic move allows the company to streamline the process of issuing v

Replimune Group (REPL) has announced the filing to offer 25.1 million shares of its common stock. This move is aimed at enabling existing shareholders to sell t

Cash and Cash Equivalents: $483.8 million as of March 31, 2025.Research and Development Expenses: $54 million for Q4 2025; $189.4 million for the fiscal year e

May 22, 2025 / 12:00PM GMTOperator Good morning, and welcome to the Replimune fiscal year fourth quarter 2025 financial results and corporate update conference

Replimune Group, Inc. (NASDAQ:REPL) Q4 2025 Results Conference Call May 22, 2025 8:00 AM ETCompany ParticipantsArleen Goldenberg - Senior Communications...

Replimune (REPL) is on the brink of a major milestone as it approaches the PDUFA date, with its commercial team fully staffed and poised to debut its first prod

”¢ BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections and late cycle review meeting complete ”

Replimune (REPL) reports FY GAAP EPS of -$3.07, missing estimates by $0.01. Cash reserves grow to $483.8M, funding operations into Q4 2026.

Replimune Group shares fell 28% on heavy volume with no news, despite a promising July 2025 PDUFA date for RP1 in advanced melanoma. Read the latest REPL stock analysis here.

WOBURN, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.

PR NewswireAUSTIN, Texas, May 8, 2025 Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna SethAUSTIN, Texas, May 8, 2025 /P

**media[618588,618589]**

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on REPL stock prospects.

U.S. stocks were lower, with the Dow Jones index falling around 700 points on Monday. Shares of Wolverine World Wide, Inc. WWW rose sharply during Monday's ses...

Replimune Group (REPL) grants inducement equity awards to 53 new employees. Awards include 98,450 stock options and 155,875 restricted stock units (RSUs).

WOBURN, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.

WOBURN, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. ( REPL), a clinical stage biotechnology company pioneering the development of novel on

WOBURN, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.